Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Colorcon
Covington
Novartis
Baxter
Julphar
Argus Health
Harvard Business School
McKinsey
Cantor Fitzgerald

Generated: August 23, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 8,623,922 protect, and when does it expire?


Patent ► Subscribe protects PERFOROMIST and is included in one NDA. There has been one Paragraph IV challenge on Perforomist.

This patent has four patent family members in three countries.

Summary for Patent: ► Subscribe

Title:Bronchodilating Beta-agonist compositions and methods
Abstract: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.
Inventor(s): Banerjee; Partha S. (Wynnewood, PA), Chaudry; Imtiaz A. (American Canyon, CA), Pham; Stephen (Sacramento, CA)
Assignee: Dey Pharma, L.P. (Basking Ridge, NJ)
Application Number:13/336,972
Patent Claim Types:
see list of patent claims
Composition; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Mylan Speclt
PERFOROMIST
formoterol fumarate
SOLUTION;INHALATION022007-001May 11, 2007RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,348,362Bronchodilating .beta.-agonist compositions and methods► Subscribe
7,541,385Bronchodilating .beta.-agonist compositions and methods► Subscribe
7,465,756Bronchodilating beta-agonist compositions and methods► Subscribe
7,462,645Bronchodilating beta-agonist compositions and methods► Subscribe
7,473,710Bronchodilating beta-agonist compositions and methods► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan200507830► Subscribe
TaiwanI359675► Subscribe
European Patent Office1660035► Subscribe
World Intellectual Property Organization (WIPO)2005007142► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Novartis
Baxter
QuintilesIMS
Dow
Johnson and Johnson
Express Scripts
Moodys
Deloitte
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot